Protect us from poor-quality medical research by 
                                                              
University of Dundee
Protect us from poor-quality medical research
ESHRE Capri Workshop Group; Ioannidis, John P.A.; Bhattacharya, Siladitya; Evers, J. L.H.;
Der Veen, Fulco Van; Somigliana, Edgardo; Barratt, Christopher L.R.; Bontempi, Gianluca;
Baird, David T.; Crosignani, Piergiorgio; Devroey, Paul; Diedrich, Klaus; Farquharson, Roy
G.; Fraser, Lynn R.; Geraedts, Joep P.M.; Gianaroli, Luca; La Vecchia, Carlo; Magli, Cristina;
Negri, Eva; Sunde, Arne; Tapanainen, Juha S.; Tarlatzis, Basil C.; Steirteghem, Andre Van;
Veiga, Anna
Published in:
Human Reproduction
DOI:
10.1093/humrep/dey056
Publication date:
2018
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
ESHRE Capri Workshop Group (2018). Protect us from poor-quality medical research. Human Reproduction,
33(5), 770-776. https://doi.org/10.1093/humrep/dey056
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
1 
Protect us from poor quality medical research 1 
Ioannidis JP, Bhattacharya S, Evers JLH, Van der Veen F, Somigliana E, 2 
Barrat C, Bontempi G, Crosignani PG on behalf of the ESHRE Capri 3 
Workshop Group1,* 4 
5 
6 
7 
Short title: Poor quality medical research 8 
9 
10 
11 
12 
13 
*Correspondence should be addressed to: P.G. Crosignani, IRCCS Ca' Granda14 
Foundation Maggiore Policlinico Hospital, Via M. Fanti, 6, 20122 Milano, 15 
Italy, e-mail: piergiorgio.crosignani@unimi.it.  16 
17 
1 The list of the ESHRE Capri Workshop Group contributors is given in the 
Appendix. 
This is a pre-copyedited, author-produced version of an article accepted for publication in Human Reproduction 
following peer review. The version of record Ioannidis, J.P.A, et al. (2018) 'Protect us from poor-quality medical 
research', Human Reproduction 33:5, pp.770-776, is available online at: https://doi.org/10.1093/humrep/dey056.
2 
 
Abstract 18 
Much of published medical research is apparently flawed, cannot be 19 
replicated and/or has limited or no utility. This paper presents an overview 20 
of the current landscape of biomedical research, identifies problems 21 
associated with common study designs and considers potential solutions. 22 
Randomized clinical trials, observational studies, systematic reviews and 23 
meta-analyses are discussed in terms of their inherent limitations and 24 
potential ways of improving their conduct, analysis and reporting. The 25 
current emphasis on statistical significance needs to be replaced by sound 26 
design, transparency and willingness to share data with a clear commitment 27 
towards improving the quality and utility of clinical research.  28 
 29 
Key words: medical research / randomized trial / observational study / 30 
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Introduction 33 
Much of published medical research is apparently flawed, cannot be replicated 34 
and/or has limited or no utility. Poor medical research has long been called a 35 
scandal (Altman 1994). Even though there have been some improvements in 36 
many research practices over time, some of the new opportunities in medical 37 
research create also more and more complex challenges on how to avoid and 38 
deal with poor research. The curricula of most medical schools do not 39 
prioritise conduct and interpretation of medical research. This creates a 40 
problem for future clinicians who wish to practice evidence based medicine, 41 
one which is compounded by the unreliability of much of published clinical 42 
research. Doctors need methodological training in order to critically appraise 43 
the quality of available evidence instead of taking all published literature on 44 
trust (Ioannidis et al, 2017). 45 
The present manuscript is based on an ESHRE Capri Workshop held in 46 
September 2017. The workshop and the resulting manuscript tried to define 47 
the main current problems underlying poor biomedical research, with 48 
emphasis on examples that would be relevant for reproductive medicine in 49 
particular; analyze the main causes; and propose changes that would solve 50 
some of these problems. This has major implications not only for research, 51 
but also for the conduct of medicine and for medical outcomes that depend on 52 
research evidence.  53 
We recognize upfront that perfectly reliable/credible and useful research is 54 
clearly an unattainable utopia. However, there are many ways in which the 55 
existing situation can be improved. In the following sections, we overview 56 
challenges in credibility and utility that affect medical research at large and 57 
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then focus on specific challenges that are more specific for some key types of 58 
influential studies: clinical trials and clinical research; big data and large 59 
observational studies; and systematic reviews and meta-analyses.   60 
OVERVIEW OF CHALLENGES IN CREDIBILITY AND UTILITY OF MEDICAL 61 
RESEARCH 62 
Most biomedical research studies are of poor quality 63 
Overall, it has been estimated that 85% of research funding is wasted, by 64 
inappropriate research questions, by irrelevant endpoints, by faulty study 65 
design and flawed execution, by poor reporting and by non-publication 66 
(MacLeod et al., 2014, Moher et al., 2016). 67 
Yet, credibility of biomedical research is an essential pre-requisite for 68 
evidence based medical decision-making. Reliability and credibility refer to 69 
how likely the results of a study are to be true. Accuracy refers to the 70 
difference between the observed results and the “truth”. Reproducibility of 71 
methods implies that use of the same methods and tools on the same data 72 
and samples will generate the same results. Reproducibility of results 73 
denotes the ability to generate comparable results in a new study using 74 
methods which are similar to those in the original study. Finally, 75 
reproducibility of inferences indicates the ability to reach similar conclusions 76 
when different individuals read the same results (Goodman et al., 2016). 77 
Apart from these essential attributes, a highly desirable characteristic of 78 
preclinical and clinical research is utility, i.e. clinical usefulness. 79 
The elusive P-value 80 
Although reliability and utility are critical, most research studies primarily 81 
aim to obtain and present significant results. Significance itself can be 82 
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conceptual, clinical, and statistical - each carrying a very specific meaning. 83 
Statistical significance (typically expressed through P-values obtained from 84 
null hypothesis testing) is almost ubiquitous in the biomedical literature. An 85 
overwhelming majority of published papers claim to have found (statistically 86 
and/or conceptually) significant results. An empirical evaluation of all 87 
abstracts published in Medline (1990-2015) reporting P-values showed that 88 
96% reported statistically significant results. In-depth analysis of close to 1 89 
million full-text papers in the same time-period identified a similarly high 90 
proportion with statistically significant P-values (Chavalarias et al., 2016). 91 
Simulation studies have shown that in the absence of a pre-specified 92 
protocol and analysis plan, analytical manipulation can produce almost any 93 
desired result as a spurious artefact (Patel et al., 2015). Multiple analyses of 94 
the same dataset can lead to  results which demonstrate variations in both 95 
magnitude and direction of effect, occasionally leading to a Janus 96 
phenomenon where different analyses of the same data provide conflicting 97 
results to the same question (Patel et al., 2015).  98 
While these problems are most prevalent in observational studies, even 99 
experimental research is not immune from them. Small and biased 100 
randomized trials can produce unreliable results. Large treatment effects  101 
produced by trials with modest sample sizes and questionable quality often 102 
disappear when the same interventions are tested in large populations by 103 
well conducted trials (Pereira et al., 2012). The literature is replete with ways 104 
of assessing quality and the risk of bias in clinical trials and other types of 105 
studies. Empirical studies have shown that deficiencies in study 106 
characteristics that reflect low quality, or high risk of bias, can lead on 107 
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average to inflated treatment effects (Savović et al., 2012). However, as the 108 
effect of quality shows large between-trial and between-topic heterogeneity, 109 
the impact of poor design in a single study cannot be accurately assessed. A 110 
low quality study should lead to greater uncertainty, but we cannot just use 111 
a correction factor to get a clean, “corrected” result.  112 
So far we have focused too much on P-values. The P value suggests a black-113 
and-white distinction that is elusive (Farland et al., 2016). Effect sizes and 114 
confidence intervals are to be preferred in studies in the context of clinically 115 
relevant questions, biological plausibility, good study design and conduct. 116 
Interpretation of data should be performed in view of prior knowledge, and 117 
should preferably lead to the generation of a scientific theory. Our goal 118 
should be to perform relevant studies (for which collective equipoise is 119 
mandatory) that have adequate power (Braakhekke et al., 2017). Their 120 
findings should be placed in the context of broader research agendas and the 121 
updated evidence should be used to inform clinical practice. 122 
The research landscape changes 123 
The landscape of clinical research is also being transformed by an increasing 124 
volume of studies from outside Europe and the USA. There is some evidence 125 
that published results from developing countries without an established 126 
tradition of clinical research tend to report larger estimates of benefits for 127 
medical interventions (Panagiotou, 2013), even in multi-centre randomised 128 
trials (De Denus et al., 2017).  129 
Commercial sponsors may design research in ways to maximize the chances 130 
of success of a new discovery, especially where large markets are involved. In 131 
these circumstances trials may not necessarily be of lower quality but the 132 
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questions may be defined and the analyses pre-specified in such ways as to 133 
yield favourable conclusions. For example, 96.5% of non-inferiority trials in 134 
2011 resulted in conclusions that favoured a new drug or intervention 135 
(Flacco et al., 2015).  136 
The advent of big data (see below) allows for more ambitious analyses but 137 
most available data are of questionable quality and the chance of uncovering 138 
genuine effects is low because of high risk of bias. Bias is separate from 139 
random error; while random error affects the precision of the signal and big 140 
data diminish the random error, bias may create signals that don’t exist or 141 
may inflate signals or cause signals in the entirely wrong direction. The 142 
availability of big data has been perceived as the dawn of a new paradigm, 143 
which liberates researchers from some of the more stringent aspects of 144 
scientific rigour such as a clear hypothesis, pre-planned analysis, validation 145 
and replication - but this is wrong. Hype surrounding new technologies can 146 
sway the best academic institutions and innovative entrepreneurs, leading to 147 
false expectations about what new tools and massive data can deliver 148 
(Lipworth et al., 2017). 149 
Utility 150 
Finally, utility is an attribute that seems to have been overlooked by much of  151 
medical research. It comprises the following key elements (Ioannidis, 2016c): 152 
having a real problem to fix; appropriate anchoring of the question within 153 
the context of prior evidence; substantial prospects of acquiring relevant new 154 
information from the new study (irrespective of the direction of its results); 155 
pragmatism; patient-centeredness (“what the patient wants”); value for 156 
money; feasibility; and transparency (including protection from bias). For a 157 
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full discussion of these 8 features of useful research see a previous 158 
discussion (Ioannidis, 2016c). Most studies published even in the very best 159 
journals meet only a minority of these features (Ioannidis, 2016c). 160 
Conflicts of interest 161 
While recent years have seen major improvements in reporting of conflicts of 162 
interest, many continue to go unreported, and there is a growing realisation 163 
that non-financial conflicts may have a bigger impact than previously 164 
imagined. High-level evidence synthesis (e.g. systematic reviews and meta-165 
analyses) and guidelines may help streamline some of the uncertainty 166 
surrounding the available evidence and facilitate medical decision-making. 167 
However, these tools also have their weaknesses (Clinical Practice Guidelines 168 
We Can Trust, 2011). As an example, a series of red flags has been proposed 169 
for guidelines (Lenzer et al., 2013), suggesting caution for those planning to 170 
use them in clinical practice. Some of these red flags are difficult to detect, 171 
e.g., when a committee for a guideline does not seem to have any major 172 
conflicts of interest among its members, but the selection of the members 173 
has been pre-emptively biased in favour of a particular recommendation, 174 
based on their known views on a subject. 175 
There are many proposed solutions to improve research practices   176 
While the challenges listed above are considerable, there is also a large body 177 
of research that has identified examples of good practice and highlighted 178 
ways of bypassing problems (Ioannidis, 2014; Munafò et al., 2017). Solutions 179 
need to be tailored to the type of study design and the questions being 180 
asked. For example, for clinical trials, preregistration of protocols and 181 
detailed description of outcomes, adoption of reporting standards, data 182 
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sharing, multi-site trials with careful selection of sites, involvement of 183 
methodological experts, appropriate regulatory oversight, and containment of 184 
conflicts of interest can all be helpful. There are still many unanswered 185 
questions about who needs to lead these positive changes in research 186 
practices: whether it is the responsibility of investigators, institutions, 187 
funders, journals, professional society, the industry, or other stakeholders. 188 
There is healthy debate on how best to protect the biomedical literature from 189 
preventable bias and error.  190 
SPECIAL CONSIDERATIONS FOR SPECIFIC, INFLUENTIAL TYPES OF 191 
MEDICAL RESEARCH 192 
A. CLINICAL TRIALS AND CLINICAL RESEARCH 193 
Clinical relevance of selected outcomes 194 
Outcomes for effectiveness studies should be relevant. Efficacy and 195 
mechanistic studies can be used judiciously to inform the best conduct of 196 
effectiveness trials with relevant outcomes. Standardization of outcomes is 197 
useful for both effectiveness and efficacy studies. Many specialties are 198 
reaching consensus on what are the core outcomes that are worth 199 
prioritizing. For example, the CROWN initiative aims at developing core 200 
outcome measures in woman’s health (Core Outcomes in Women's Health 201 
(CROWN) Initiative, 2014). 202 
Multiplicity issues in clinical research 203 
If researchers perform many analyses, some will turn out to be statistically 204 
significant purely by chance, yielding false-positive results. Multiple testing 205 
might represent a particular problem in infertility treatment: due to the 206 
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multistage nature of many treatments, many outcomes may be reported in a 207 
study.  208 
Registration 209 
Registration of clinical research has become more common, especially for 210 
clinical trials, but still many trials are not pre-registered. Ideally, before 211 
carrying out a clinical trial, its full study design, including all primary and 212 
secondary outcomes (e.g. number of oocytes obtained per woman 213 
randomised, or cumulative live birth rate after three completed cycles of ART 214 
treatment), should be pre-specified and the trial registered in a WHO 215 
approved clinical trial registry, together with the latest approved version of 216 
the protocol (COMPare, 2017). In the absence of registration (or with 217 
incomplete details about registration), it is not possible to tell what goals, 218 
objectives, design aspects, or analyses were pre-specified versus post-hoc 219 
explorations.  220 
Reporting of pre-specified outcomes 221 
Once the trial is finished, the trial report should present all pre-specified 222 
outcomes. When reported outcomes differ from those pre-specified, this must 223 
be declared in the report, along with an appropriate explanation (COMPare, 224 
2017). Changing endpoints of a study after the analysis of the data has 225 
occurred may denote scientific misconduct, especially if the change is 226 
instigated by the lack of significance in the primary outcome, but not in 227 
some arbitrary subordinate outcomes (COMPare, 2017). This is popularly 228 
known as P-hacking, data dredging, cherry picking, snooping, significance 229 
chasing, or the Texas sharpshooter fallacy (Evers, 2017).  230 
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Reporting guidance exists for randomized trials (CONOSRT), as well as for 231 
other types of clinical research, e.g. STARD (for diagnostic test studies), 232 
PRISMA (for meta-analyses) and IMPRINT (the latter specifically for fertility 233 
trials). These guidance documents aim to improve the quality and 234 
completeness of clinical research reports (Glasziou et al., 2014). It is very 235 
disturbing that comparisons of protocols with publications in major medical 236 
journals revealed that most studies had at least one primary endpoint 237 
changed, introduced, or omitted (Chan et al., 2004; Chan et al., 2014; 238 
Glasziou et al., 2014).  239 
Power considerations in clinical trials 240 
Lack of sufficient power is a major problem across various types of studies, 241 
including randomized trials in diverse disciplines and reproductive medicine 242 
is no exception. Differences in live birth rates of 3-5% may still be clinically 243 
relevant to detect, but hardly any trials in the field have sufficient sample 244 
size for this. Therefore, one should be careful in interpreting confidence 245 
intervals. Some trials where it is concluded that “the intervention had no 246 
effect” may in fact offer no conclusive information about whether the 247 
treatment is effective or not. Moreover, small trials are more likely to 248 
generate exaggerated effects and even false-positive spurious effects. 249 
BIG DATA AND LARGE OBSERVATIONAL DATASETS 250 
Database linkage: maximum temptation meets maximum opportunity  251 
Sources of health care data include governments, healthcare providers, 252 
insurers, registries of specific conditions, treatments and medical devices, as 253 
well as registers of births and deaths. Increasingly, data are available in 254 
electronic formats and can be linked with other health, social, geographical 255 
12 
 
and education data to create massive datasets incorporating complex 256 
longitudinal records with large-scale population coverage and long-term 257 
follow-up. Medical records can provide demographic information, lifestyle 258 
choices, clinical findings, laboratory and imaging results, treatment details 259 
and outcomes. Ability to link sociodemographic and clinical details with 260 
genomic, proteomic, and metabolomic data could potentially allow physicians 261 
to deliver precision medicine (Peek et al., 2014) for individual patients. 262 
Routinely collected health data can also allow a real-world evaluation of 263 
treatment outcomes.   264 
 While opportunities seem to abound in theory, there are many serious 265 
limitations to big data and large observational datasets. Here we discuss some 266 
of the key ones. 267 
Problems with information 268 
The event-based nature of routinely collected health data is a potential 269 
limitation, as important problems or treatments not resulting in hospital 270 
contacts may be missing. Inaccuracies in the data can occur due to mistakes 271 
in data entry and lack of appropriate checks. Routine data are also likely to 272 
contain a minimum set of variables and many key confounders such as body 273 
weight, height, smoking status, alcohol intake and socio-economic status may 274 
be missing. Many historical datasets lack a planned schema, which can create 275 
problems during analysis (Jorm, 2015) although others have detailed 276 
metadata (Ayorinde et al., 2016). Finally, data is often missing in a non-277 
random fashion thus introducing the possibility of bias. While some ways of 278 
dealing with missing data (Jagsi et al., 2014) are better than others, 279 
missingness may be difficult to address with high confidence. 280 
13 
 
Ethical challenges 281 
Major concerns arise around the use of routinely collected data to answer 282 
questions for which the data were not originally collected. These concerns 283 
involve lack of informed consent, possible identification of subjects during 284 
linkage procedures (even after anonymisation), the dilemma of dealing with 285 
detected individual risks in an anonymised (rather than anonymous) 286 
population who could potentially be identified and informed  and individuals 287 
in very small categories of groups with unusual conditions. Instead of widely 288 
open use of big data, it may be required to employ data safe havens where 289 
access is limited to trained staff and safe release of data after rigorous checks 290 
to minimise risks of identification (Lea et al., 2016). 291 
Difficulties in linkage  292 
Linkage presents a common technical challenge which could introduce 293 
significant error if done incorrectly. The most accurate is the deterministic 294 
method using a unique identifier, such as the personal identity number in the 295 
Nordic countries and the community health index (CHI) number in Scotland 296 
(Ayorinde et al., 2016). Where this is not feasible, probabilistic methods based 297 
on characteristics such as name, date of birth, geographical location have 298 
been used but this approach can result in errors.   299 
Dealing with confounding in large observational datasets 300 
All large observational datasets are prone to confounding that can cause 301 
spurious associations. For example, in the context of fertility data, age is a 302 
common confounder which influences the choice of treatment as well as its 303 
outcome. Often choice of therapy is usually based on preference, predicted 304 
response, or other non-random selection features which can impact on 305 
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outcomes (Jagsi et al., 2014). For example, as women with more severe 306 
endometriosis may be more likely to receive surgery than women with less 307 
severe disease, the outcome of surgical treatment may appear to be worse than 308 
medical alternatives. Methods such as propensity score matching, propensity 309 
score stratification, inverse probability of treatment weighting and 310 
instrumental variable analysis, which uses counterfactuals to try to 311 
approximate a randomized design situation, try to address this problem. 312 
Although some reviews (Anglemyer et al., 2014) suggest that there is limited 313 
evidence for significant differences in health care outcomes between 314 
observational studies and randomised trials, other studies show that further 315 
refinements in analysis need to be made in order to achieve the same degree 316 
of accuracy (McGale et al., 2016). Empirical evaluations suggest that routinely 317 
collected data are not yet used to their maximal potential utility (Hemkens et 318 
al., 2016a), and they tend to generate inflated treatment effects even when 319 
sophisticated propensity score methods are used (Hemkens et al., 2016b).  320 
Overpowered big data 321 
Studies based on large datasets can have sample sizes that are so large that 322 
they detect very small and clinically unimportant effect sizes. Such studies 323 
should be interpreted appropriately according to their clinical significance. 324 
Highly statistically significant results may still represent pure chance findings 325 
(Peek et al., 2014). With small effects, bias or confounding cannot be excluded. 326 
Interpretation must therefore be cautious, despite whatever statistical 327 
significance.  328 
Personalised medicine prospects 329 
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Advances in computational infrastructures for dealing with big datasets and 330 
the related explosion in data science methodology, lead to speculations that 331 
the future of life sciences is likely to be dominated by systems which can 332 
ingest and sift through large volumes of -omics data to generate reliable 333 
information for individualised decision making (e.g. personalised [precision] 334 
medicine). However, these expectations have yet to be fully realized. A naïve 335 
expectation of accurate predictions from inherently flawed and incomplete 336 
data could turn out to be no more than blind faith in fool’s gold (Khoury et 337 
al., 2014; Lipworth et al., 2017). Personalised medicine is an interesting 338 
concept but it meets with many conceptual (Senn, 2016) and practical 339 
difficulties in making it work.  340 
SYSTEMATIC REVIEWS AND META-ANALYSES 341 
A prolific industry of meta-analyses 342 
Most hierarchies of evidence place well-conducted systematic reviews (SRs) 343 
and meta-analyses (MAs) at the top of the evidence pyramid and these 344 
publications have grown in volume as well as influence. As of mid-2017, 345 
nearly 100,000 published meta-analysis articles were indexed in PubMed 346 
with over 1000 new ones indexed every month (Ioannidis, 2016a). There are 347 
also approximately 250,000 published SRs in PubMed, with another 2500 348 
new ones indexed every month. In many fields there are more SRs than 349 
primary studies (Prior et al., 2017) and, in many situations, SRs have 350 
replaced experience and clinical acumen in terms of driving clinical decision 351 
making. This has not gone unnoticed by individuals and groups with vested 352 
interests (financial or non-financial) who have used them as tools to 353 
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influence practice in favour of their preferred drugs and interventions 354 
(Ioannidis, 2016b).  355 
Most SRs and MAs are not very useful and many are not useful at all  356 
A common conclusion of many systematic reviews, particularly those that 357 
address questions on effective treatment is that primary evidence is lacking, 358 
suboptimal or unreliable. This statement alone has some utility, because it 359 
can still help calibrate the level of uncertainty in decision making and may 360 
suggest avenues of new research. However, very often the primary data 361 
feeding into SRs and MAs are so unreliable that these may have a more 362 
important role in detecting bias rather than uncovering the truth. SRs and 363 
MAs may also help identify gaps in the use of patient-relevant outcomes 364 
where multiple studies exist but outcomes that matter are not addressed.  365 
The global profile of  SRs and MAs 366 
The profile of SRs and MAs has changed over the last decade, with 367 
increasing numbers of Mas now being generated in China. Most of these MAs 368 
are unreliable, or misleading (especially the bulk-produced meta-analyses of 369 
candidate gene associations). Moreover, there is a new large portfolio of MAs 370 
conducted by contractor companies that are commissioned and paid by the 371 
industry (Schuit and Ioannidis, 2016). Only a small proportion of these MAs 372 
are published and publication bias may be related to the results of the MAs 373 
and the interests of the sponsor. An online search suggested that over 100 374 
service-offering companies perform SRs and MAs (Schuit and Ioannidis, 375 
2016).  376 
Redundancy in SRs and MAs 377 
17 
 
A recent evaluation suggested that only about 3% of current MAs are both 378 
methodologically sound and clinically useful (Ioannidis, 2016a). There is a 379 
lot of redundancy and large numbers of SRs and MAs continue to be 380 
conducted on some topics without clear evidence for the additional value of 381 
the newer publications, e.g. in the area of urinary derived versus 382 
recombinant FSH treatment (Van Wely et al, 2011).  383 
More sophisticated MA designs 384 
Even for more sophisticated forms of evidence synthesis such as network 385 
MAs, an empirical evaluation identified 28 publications on the same topic, 386 
each including part of the available evidence with inconsistent conclusions 387 
(Naudet et al., in press). Registration of MAs at the protocol stage, e.g. in 388 
registries like PROSPERO, may be helpful, but it is unclear whether this 389 
alone can create a more efficient, transparent and, ultimately, a more 390 
accurate compilation of all the available facts (Tricco et al., 2016; Moher et 391 
al., 2014).  392 
An increasing number of MAs have been able to use individual participant 393 
data. These require more resources to perform compared with MAs of 394 
aggregated data, but they have a number of advantages in terms of being 395 
able to clean the data, standardize definitions, outcomes and co-variates 396 
across studies, and can explore subgroup differences in a more reliable 397 
fashion (Simmonds et al., 2005). Apart from higher costs, their disadvantage 398 
includes incomplete retrieval of data, potentially leading to bias, if some 399 
trials with specific directions of effect are missed. As results from 400 
randomized trials and other types of studies become more readily available, 401 
it may be easier to perform comprehensive MAs using individual-level data in 402 
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the future.  Using advanced meta-analysis methods requires statistical and 403 
methodological competence that if often currently lacking in reviewers 404 
undertaking such analyses using software that they don’t fully understand 405 
how they function.  406 
Systematic reviews and meta-analyses in the future 407 
Despite limitations, SRs and MAs will continue to be indispensable for 408 
summarizing the evidence and understanding its biases, strengths, and 409 
weaknesses. Moving forward, hopefully there will be more MAs in the future 410 
which use optimal methods for systematic searches, retrieving, analysing 411 
and reporting data.  It is also likely that there will be more MAs that will use 412 
either networks or individual-level data or both, allowing for more 413 
informative analyses and data syntheses. Eventually, MAs may be planned 414 
as prospective exercises, i.e. designed contemporaneously with primary 415 
evaluative studies with a clear a priori plan of combining results from 416 
primary studies on completion (Ioannidis, 2017). This approach may help to 417 
minimize some of the biases that exist in retrospective data synthesis.  418 
THE FUTURE 419 
Given the challenges described above, it is probably not surprising that most 420 
medical research shows poor reproducibility of methods and results. Some of 421 
the problems are increasingly recognized by the scientific community. A 422 
2016 Nature survey showed that more than two-thirds of scientists believed 423 
that there is a reproducibility problem (Baker, 2017). Replicability is a 424 
benchmark of scientific quality; authors should always try to replicate their 425 
own results and provide sufficiently detailed instructions for others to do so. 426 
While research fraud is uncommon, the temptation to cut corners prompts 427 
19 
 
many authors to indulge in poor scientific practices (Tanksalva, 2017). The 428 
“publish or perish” attitude favours hasty, low quality, incomplete research 429 
with the aim of maximising the number of papers from a single research 430 
project (salami slicing). There is also a temptation to sensationalize results. 431 
Incentive structures for rewarding research, e.g. publication, funding, 432 
promotion, and tenure, need to pay more attention to quality and 433 
reproducibility of the work produced.  434 
Investigators can learn from studies which cannot be replicated. Adoption of 435 
reporting standards will help, as will multi-site trials, involvement of 436 
methodological experts, appropriate regulatory oversight, and transparency 437 
about conflicts of interest. As gatekeepers, journals can offer high quality 438 
peer review (which should include proper statistical/methodological review, 439 
as appropriate). Prospective trial registration is not enough, full protocols 440 
should also be published, and data should be shared.  441 
Finally, many changes will require emphasis on education, including 442 
training at medical schools (physicians should be sensitized to strengths and 443 
weaknesses of the evidence that affects their practices) and training of 444 
researchers in methodological competence. 445 
 446 
 447 
 448 
 449 
 450 
  451 
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